Concepedia

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Robert L. Ferris, Maura L. Gillison, Jérôme Fayette, Amaury Daste, P. Koralewski, R. Mesía Nin, Nabil F. Saba,

Annals of Oncology · 2021 · 31 citations · 0 references

Concepts

MedicineOncologyPharmacotherapyCancer PharmacologyMetastasisOncology PharmacotherapyCancer ImmunotherapyImmunotherapy For Solid TumorsMalignant NeoplasmsSquamous Cell CarcinomaTargeted Cancer TherapyTargeted TherapyManagement Of N1 DiseaseMetastatic Squamous Cell CarcinomaTargeted Therapy For RecurrenceTherapy Response Evaluation